Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo

Ali, 2006, A novel small reporter gene and HIV-1 fitness assay, J. Virol. Methods, 133, 41, 10.1016/j.jviromet.2005.10.016 Alvarez, 2014, HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells, J. Virol., 88, 6031, 10.1128/JVI.00449-14 Andris, 1991, Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response, Proc. Natl. Acad. Sci. USA, 88, 7783, 10.1073/pnas.88.17.7783 Andrus, 1998, Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant, J. Infect. Dis., 177, 889, 10.1086/515251 Arias, 2014, Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity, Proc. Natl. Acad. Sci. USA, 111, 6425, 10.1073/pnas.1321507111 Balazs, 2011, Antibody-based protection against HIV infection by vectored immunoprophylaxis, Nature, 481, 81, 10.1038/nature10660 Barouch, 2013, Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys, Cell, 155, 531, 10.1016/j.cell.2013.09.061 Barouch, 2015, Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys, Science, 349, 320, 10.1126/science.aab3886 Baum, 1996, HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression, J. Immunol., 157, 2168, 10.4049/jimmunol.157.5.2168 Bonsignori, 2012, Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family, J. Virol., 86, 11521, 10.1128/JVI.01023-12 Bournazos, 2014, Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity, Cell, 158, 1243, 10.1016/j.cell.2014.08.023 Bradley, 2016, Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity, EBioMedicine, 12, 196, 10.1016/j.ebiom.2016.08.045 Bruel, 2017, Lack of ADCC breadth of human nonneutralizing anti-HIV-1 antibodies, J. Virol., 91, e02440-16, 10.1128/JVI.02440-16 Burton, 2011, Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody, Proc. Natl. Acad. Sci. USA, 108, 11181, 10.1073/pnas.1103012108 Caskey, 2015, Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117, Nature, 522, 487, 10.1038/nature14411 Caskey, 2017, Antibody 10-1074 suppresses viremia in HIV-1-infected individuals, Nat. Med., 23, 185, 10.1038/nm.4268 Chung, 2011, Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure, Proc. Natl. Acad. Sci. USA, 108, 7505, 10.1073/pnas.1016048108 Chung, 2014, Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function, AIDS, 28, 2523, 10.1097/QAD.0000000000000444 Churchill, 1994, Crystal structure of a peptide complex of anti-influenza peptide antibody Fab 26/9. Comparison of two different antibodies bound to the same peptide antigen, J. Mol. Biol., 241, 534, 10.1006/jmbi.1994.1530 Demberg, 2007, J. Virol., 81, 3414, 10.1128/JVI.02453-06 DeVico, 2007, Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens, Proc. Natl. Acad. Sci. USA, 104, 17477, 10.1073/pnas.0707399104 Diskin, 2011, Increasing the potency and breadth of an HIV antibody by using structure-based rational design, Science, 334, 1289, 10.1126/science.1213782 Escolano, 2017, Progress toward active or passive HIV-1 vaccination, J. Exp. Med., 214, 3, 10.1084/jem.20161765 Ferrari, 2017, Humoral and innate antiviral immunity as tools to clear persistent HIV infection, J. Infect. Dis., 215, S152, 10.1093/infdis/jiw555 Florese, 2009, Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines, J. Immunol., 182, 3718, 10.4049/jimmunol.0803115 Fouts, 2015, Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection, Proc. Natl. Acad. Sci. USA, 112, E992, 10.1073/pnas.1423669112 Gautam, 2016, A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges, Nature, 533, 105, 10.1038/nature17677 Gnanakaran, 2010, Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies, PLoS Comput. Biol., 6, e1000955, 10.1371/journal.pcbi.1000955 Halper-Stromberg, 2014, Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice, Cell, 158, 989, 10.1016/j.cell.2014.07.043 Haynes, 2012, Immune-correlates analysis of an HIV-1 vaccine efficacy trial, N. Engl. J. Med., 366, 1275, 10.1056/NEJMoa1113425 Hessell, 2007, Fc receptor but not complement binding is important in antibody protection against HIV, Nature, 449, 101, 10.1038/nature06106 Hidajat, 2009, Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques, J. Virol., 83, 791, 10.1128/JVI.01672-08 Holl, 2004, Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages, J. Immunol., 173, 6274, 10.4049/jimmunol.173.10.6274 Holl, 2006, Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells, J. Virol., 80, 6177, 10.1128/JVI.02625-05 Horwitz, 2013, HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice, Proc. Natl. Acad. Sci. USA, 110, 16538, 10.1073/pnas.1315295110 Igarashi, 1999, Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma, Nat. Med., 5, 211, 10.1038/5576 Klein, 2012, HIV therapy by a combination of broadly neutralizing antibodies in humanized mice, Nature, 492, 118, 10.1038/nature11604 Klein, 2013, Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization, Cell, 153, 126, 10.1016/j.cell.2013.03.018 Klein, 2013, Antibodies in HIV-1 vaccine development and therapy, Science, 341, 1199, 10.1126/science.1241144 Kramski, 2013, HIV-specific antibody immunity mediated through NK cells and monocytes, Curr. HIV Res., 11, 388, 10.2174/1570162X113116660061 Kwong, 1998, Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody, Nature, 393, 648, 10.1038/31405 Lambotte, 2009, Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers, AIDS, 23, 897, 10.1097/QAD.0b013e328329f97d Lewis, 2013, Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies, Curr. HIV Res., 11, 354, 10.2174/1570162X113116660060 Lewis, 2017, Survivors remorse: antibody-mediated protection against HIV-1, Immunol. Rev., 275, 271, 10.1111/imr.12510 Li, 2006, Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1, J. Virol., 80, 5211, 10.1128/JVI.00201-06 Liao, 2013, Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2, Immunity, 38, 176, 10.1016/j.immuni.2012.11.011 Lu, 2016, Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo, Science, 352, 1001, 10.1126/science.aaf1279 Margolis, 2017, HIV antibodies for treatment of HIV infection, Immunol. Rev., 275, 313, 10.1111/imr.12506 Mascola, 1999, Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies, J. Virol., 73, 4009, 10.1128/JVI.73.5.4009-4018.1999 Moldt, 2016, Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques, AIDS, 30, 1543, 10.1097/QAD.0000000000001102 Moog, 2014, Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques, Mucosal Immunol., 7, 46, 10.1038/mi.2013.23 Moore, 1990, Dissociation of gp120 from HIV-1 virions induced by soluble CD4, Science, 250, 1139, 10.1126/science.2251501 Moore, 2006, Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1, J. Virol., 80, 2515, 10.1128/JVI.80.5.2515-2528.2006 Moran, 1993, Variable region genes of anti-HIV human monoclonal antibodies: non-restricted use of the V gene repertoire and extensive somatic mutation, Mol. Immunol., 30, 1543, 10.1016/0161-5890(93)90462-K Mouquet, 2011, Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses, PLoS ONE, 6, e24078, 10.1371/journal.pone.0024078 Nyambi, 2000, Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M, J. Virol., 74, 7096, 10.1128/JVI.74.15.7096-7107.2000 Pegu, 2014, Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor, Sci. Transl. Med., 6, 243ra88, 10.1126/scitranslmed.3008992 Pegu, 2017, Use of broadly neutralizing antibodies for HIV-1 prevention, Immunol. Rev., 275, 296, 10.1111/imr.12511 Pham, 2014, HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2, Retrovirology, 11, 15, 10.1186/1742-4690-11-15 Pham, 2016, Enhancing virion tethering by BST2 sensitizes productively and latently HIV-infected T cells to ADCC mediated by broadly neutralizing antibodies, Sci. Rep., 6, 37225, 10.1038/srep37225 Pietzsch, 2012, A mouse model for HIV-1 entry, Proc. Natl. Acad. Sci. USA, 109, 15859, 10.1073/pnas.1213409109 Rerks-Ngarm, 2009, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand, N. Engl. J. Med., 361, 2209, 10.1056/NEJMoa0908492 Richard, 2015, Small CD4 mimetics prevent HIV-1 uninfected bystander CD4 + T cell killing mediated by antibody-dependent cell-mediated cytotoxicity, EBioMedicine, 3, 122, 10.1016/j.ebiom.2015.12.004 Robb, 2012, Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144, Lancet Infect. Dis., 12, 531, 10.1016/S1473-3099(12)70088-9 Salazar-Gonzalez, 2008, Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing, J. Virol., 82, 3952, 10.1128/JVI.02660-07 Santra, 2015, Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques, PLoS Pathog., 11, e1005042, 10.1371/journal.ppat.1005042 Scheid, 2009, Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals, Nature, 458, 636, 10.1038/nature07930 Scheid, 2016, HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption, Nature, 535, 556, 10.1038/nature18929 Shingai, 2014, Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques, J. Exp. Med., 211, 2061, 10.1084/jem.20132494 Smith, 2012, Mouse model recapitulating human Fcγ receptor structural and functional diversity, Proc. Natl. Acad. Sci. USA, 109, 6181, 10.1073/pnas.1203954109 Song, 2010, Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients, J. Virol., 84, 6935, 10.1128/JVI.00453-10 Tomaras, 2008, Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia, J. Virol., 82, 12449, 10.1128/JVI.01708-08 Tomaras, 2013, Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG, Proc. Natl. Acad. Sci. USA, 110, 9019, 10.1073/pnas.1301456110 Wei, 2003, Antibody neutralization and escape by HIV-1, Nature, 422, 307, 10.1038/nature01470 West, 2013, Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues, Proc. Natl. Acad. Sci. USA, 110, 10598, 10.1073/pnas.1309215110 Wyatt, 1995, Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding, J. Virol., 69, 5723, 10.1128/jvi.69.9.5723-5733.1995 Xu, 1991, Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies, J. Virol., 65, 4832, 10.1128/jvi.65.9.4832-4838.1991 Zolla-Pazner, 1995, Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry, J. Virol., 69, 3807, 10.1128/jvi.69.6.3807-3815.1995 Zolla-Pazner, 2013, Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial, PLoS ONE, 8, e53629, 10.1371/journal.pone.0053629 Zolla-Pazner, 2014, Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection, PLoS ONE, 9, e87572, 10.1371/journal.pone.0087572